Clinical Trial Update: A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age [Phase 1]

View source ↗

Summary

Phase I randomized, observer-blinded, dose-ranging study of an RSV vaccine in healthy children aged 24 to under 72 months completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Snippet

Sponsor: Novavax | Conditions: Respiratory Synctial Virus | Phase 1 | Status: COMPLETED